Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

Gastroenterology

Volumn 128, Issue 7, 2005, Pages 1890-1897

  Sung, Joseph J Y ^a,d   Wong, May Ling ^a   Bowden, Scott ^b   Liew, Choong Tsek ^a   Hui, Alex Y ^a   Wong, Vincent W S ^a   Leung, Nancy W Y ^c   Locarnini, Stephen ^b   Chan, Henry L Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; HEPATITIS B ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOME; HEPATITIS B VIRUS; HUMAN; MALE; PATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VIRUS INFECTION;

EID: 20444505037     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.03.009     Document Type: Article

References (30)

1. Y.F. Liaw, N.W.Y. Leung, T.T. Chang, R. Guan, D.I. Tai, K.Y. Ng, R.N. Chien, J. Dent, L. Roman, S. Edmundson, C.L. Lai Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 2000 172 180
2. J.I. Dienstag, J. Cianciara, S. Karayalcin, K.V. Kowdley, B. Willems, S. Plisek, M. Woessner, S. Gardner, E. Schiff Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 2003 748 755
3. B.C. Song, D.J. Suh, H.C. Lee, Y.H. Chung, Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
4. A.B. Van Nunen, B.E. Hansen, D.J. Suh, H.F. Lohr, L. Chemello, H. Fontaine, J. Heathcote, B.C. Song, H.L.A. Janssen, R.A. de Man, S.W. Schalm Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 2003 420 424
5. G.V. Papatheodoridis, E. Manesis, S.J. Hadziyannis The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313
6. A.S.F. Lok, B.J. McMahon Chronic hepatitis B Hepatology 34 2002 1225 1241
7. J. Tuttleman, C. Pourcel, J. Summers Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells Cell 47 1986 451 460
8. J. Newbold, H. Xin, M. Tencza, G. Sherman, J. Dean, S. Bowden, S. Locarnini The convalently closed duplex form of the hepadenavirus genome exists in isute as a heterogeneous population of viral minichromosomes J Virol 69 1995 3350 3357
9. J. Dean, S. Bowden, S. Locarnini Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir Antiviral Res 27 1995 171 178
10. M. Kuhns, A. McNamara, A. Mason, C. Campbell, R. Perrillo Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen Gastroenterology 103 1992 1649 1656
11. T.L. Fong, A.M. Di Bisceglie, M.A. Gerber, J.G. Waggoner, J.H. Hoofnagle Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B Hepatology 18 1993 1313 1318
12. M.A. Loriot, P. Marcellin, F. Walker, N. Boyer, C. Degott, I. Randrianatoavina, J.P. Benhamou, S. Erlinger Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg J Hepatol 27 1997 251 258
13. G. Moraleda, J. Saputelli, C.E. Aldrich, D. Averett, L. Condreay, W.S. Mason Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus J Virol 71 1997 9392 9399
14. S. Bowden, K. Jackson, M. Littlejohn, S. Locarnini Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR Methods Mol Med 95 2004 41 50
15. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, G. Lau, C. Trepo, P. Marcellin, Z. Goodman, W.E. Delaney IV, S. Xiong, C.L. Brosgart, S.S. Chen, C.S. Gibbs, F. Zoulim Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758
16. H.L.Y. Chan, N.W.Y. Leung, A.Y. Hui, V.W.S. Wong, C.T. Liew, A.M.L. Chim, F.K.L. Chan, L.C.T. Hung, Y.T. Lee, J.S.L. Tam, C.W.K. Lam, J.J.Y. Sung Peginterferon alfa-2b and lamivudine versus lamivudine alone for chronic hepatitis B. A randomized controlled trial Ann Intern Med 142 2005 240 250
17. H.L.Y. Chan, N.W.Y. Leung, T.C.M. Lau, M.L. Wong, J.J.Y. Sung Comparison of three different sensitive assays for hepatitis B virus (HBV) DNA in monitoring response of anti-viral therapy J Clin Microbiol 38 2000 3205 3208
18. K.R. Loeb, K.R. Jerome, J. Goddard, M.L. Huang, A. Cent, L. Corey High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system Hepatology 32 2000 626 629
19. H.L.Y. Chan, A.K.K. Chui, W.Y. Lau, F.K.L. Chan, M.L. Wong, C.H. Tse, A.R.N. Rao, J. Wong, J.J.Y. Sung Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation J Med Virol 68 2002 182 187
20. A.S. Lok, F. Zoulim, S. Locarnini, A. Mangia, G. Niro, H. Decraemer, G. Maertens, F. Hulstaert, K. De Vreese, E. Sablon Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy evaluation of performance of INNO-LiPA HBV DR assay J Clin Microbiol 40 2002 3729 3734
21. L. Stuyver, S.A. Locarnini, A. Lok, D.D. Richman, W.F. Carman, J.L. Dienstag, R.F. Shinazi Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region Hepatology 33 2001 751 757
22. C.L. Lai, J. Dienstag, E. Schiff, N.W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, L. Condreay Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696
23. P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, S. Locarnini Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292 297
24. G. Fattovich, G. Giustina, G. Realdi, R. Corrocher, S.W. Schalm Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 26 1997 1338 1342
25. P. Lampertico, E. Del Ninno, M. Vigano, R. Romeo, M.F. Donato, E. Sablon, A. Morabito, M. Colombo Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763
26. K.M. Lee, S.W. Cho, S.W. Kim, H.J. Kim, K.B. Hahm, J.H. Kim Effect of virological response on post-treatment durability of lamivudine induced HBeAg seroconversion J Viral Hepatol 9 2002 208 212
27. R.N. Chien, C.T. Yeh, S.L. Tsai, C.M. Chu, Y.F. Liaw Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 2003 1267 1273
28. C.M. Lee, G.Y. Ong, S.N. Lu, J.H. Wang, C.A. Liao, H.D. Tung, T.M. Chen, C.S. Changchien Durability of lamivudine induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation J Hepatol 37 2002 669 674
29. A.S. Lok, O.C. Ma, J.Y. Lau Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver Gastroenterology 100 1991 756 761
30. L.G. Guidotti, S. Guilhot, F.V. Chisari Interleukin-2 and α/β interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways J Virol 68 1994 1265 1270